Literature DB >> 23884822

The current status of combination therapy of chronic hepatitis B.

E-Q Chen1, H Tang.   

Abstract

In the past decade, the treatment of chronic Hepatitis B (CHB) has been revolutionized by the increased availability of effective antiviral agents. However, there is an alarming of the increasing rates of viral resistance and suboptimal response in CHB patients with single drug therapy. Recently, the strategy of combination therapy for CHB has been proposed and concerned by clinicians. In this review, using PubMed and web of science as main searching tools, we evaluated various latest research reports on combination therapy for CHB, and made a summary of the progress of combination antiviral therapy and outline areas that need to be addressed in the future.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23884822

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

Review 1.  Optimization therapy for the treatment of chronic hepatitis B.

Authors:  En-Qiang Chen; Hong Tang
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

2.  New universal primers for genotyping and resistance detection of low HBV DNA levels.

Authors:  Yongqing Tong; Bei Liu; Hui Liu; Hongyun Zheng; Jian Gu; Hang Liu; Min Lin; Yali Ding; Chunhua Song; Yan Li
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

3.  Autologous bone marrow stem cell transplantation via the hepatic artery for the treatment of hepatitis B virus-related cirrhosis: a PRISMA-compliant meta-analysis based on the Chinese population.

Authors:  Ani Sun; Wenni Gao; Ting Xiao
Journal:  Stem Cell Res Ther       Date:  2020-03-05       Impact factor: 6.832

4.  Effect of Liuweiwuling tablet on biochemical and virological parameters, and quality of life in patients with hepatitis B virus-related cirrhosis: A protocol for a systematic review and meta-analysis.

Authors:  Ding Li; Min Zhu; Changhui Zhou; Xiujing Liu
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.